FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Tercica news from FierceBiotech

News

Ipsen inks a string of deals in expansion effort

France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...

C&L: Lundbeck CEO resigns early

Denmark's H Lundbeck announced that its president and chief executive Claus Braestrup has resigned earlier than expected. Critical Therapeutics announced that Frank Thomas will resign as president Read more...

FDA approves Tercica's growth disorder drug

The FDA has approved Tercica's Somatuline Autogel, an injectable treatment for adult patients with acromegaly. Acromegaly is a rare disorder caused by too much growth hormone, resulting in enlarged Read more...
Tags: Tercica   Ipsen   FDA   injectable   milestones  

ALSO NOTED: Pharmaxis touts late-stage study; ALS gains orphan drug status; H5N1 passed human-to-human; and much more...

> Pharmaxis says that a late-stage study of its experimental drug for a chronic lung condition demonstrated its effectiveness. Read more...